Last updated: June 9, 2026
Delsym (dextromethorphan) suppliers and manufacturers: who makes it, who supplies it, and where the supply chain bottlenecks sit
Delsym is a branded cough suppressant built around dextromethorphan (most often dextromethorphan polistirex in an extended-release format). In practice, the “supplier” picture breaks into three layers: (1) active ingredient suppliers (dextromethorphan polistirex or dextromethorphan HBr base), (2) finished-dose manufacturers that produce Delsym bottles/liquid, and (3) contractors that provide excipients, packaging, and fill-finish logistics. Public disclosure is fragmented because multiple labeled strengths and label configurations exist, and many manufacturers build finished dosage forms under private-label or licensing models.
Who manufactures Delsym cough syrup (dextromethorphan polistirex) in the US?
Featured-snippet answer: Delsym is marketed in the US under the framework of Sanofi Consumer Healthcare (brand owner for cough/cold products historically), with manufacturing carried out by third-party contract manufacturers and/or affiliate sites that perform formulation, bulk hold, and fill-finish for the finished liquid dosage form.
How to identify the actual “manufacturer” on the label
The most reliable way to map “who supplies Delsym” is label- and lot-level identification:
- Distributor/labeler: the marketing party shown as the “Distributed by” or “Manufactured for” entity.
- Manufacturer: the site entity shown with address near “Manufactured by” / “Packaged by.”
- NDC-linked manufacturing site: the site often changes across time, strengths, or packaging sizes.
Because Delsym exists in multiple strengths and pack formats, a single manufacturer name is not stable across the product line.
What suppliers provide the active ingredient for Delsym (dextromethorphan polistirex)?
Featured-snippet answer: Delsym’s active ingredient supply is anchored in the dextromethorphan API and/or polymerized salt system used for extended-release, typically obtained from specialized API and polymer-salt suppliers.
API supply chain structure for dextromethorphan-based extended release
For dextromethorphan extended-release liquids, supply generally involves:
- Dextromethorphan base or salt supply (HBr or other controlled form used in processing).
- Polistirex-based extended-release carrier preparation (polymer and controlled release particle properties).
- Quality-qualified conversion into the specific extended-release intermediate used in finished syrup.
This segment is concentrated among API manufacturers that can deliver tight specs for:
- particle size distribution (for polymeric extended release behavior),
- impurity profiles,
- residual solvents and heavy metals controls.
Which contract manufacturers make extended-release dextromethorphan liquid for retail brands like Delsym?
Featured-snippet answer: Dextromethorphan ER liquids are commonly made by specialty liquid-dose CDMOs that run:
- solvent blending and controlled granulation (if the formulation uses a polymeric ER intermediate),
- controlled viscosity and suspension homogeneity validation,
- large-scale fill-finish for oral liquids.
Common fill-finish and packaging workstreams
Suppliers supporting the “Delsym bottle” supply chain typically include:
- batch release testing labs (in-house or outsourced),
- microbiology and stability testing vendors,
- bottle and cap suppliers (tamper evidence, child-resistant caps),
- secondary packaging (cartons, leaflets, shrink-wrap).
How does the Delsym supply chain differ for store brand vs branded bottles?
Featured-snippet answer: The branded supply chain is often “brand-owned QMS + outsourced manufacturing,” while store-brand versions can add private-label labeling and sometimes different packaging vendors. The API and formulation chemistry typically stay similar, while site ownership, packaging line, and lot release documentation differ.
Key practical differences
- Labeling and regulatory documentation: differs by NDC and label strength.
- Packaging components: child-resistant and tamper-evident designs vary.
- Manufacturing site rotation: more likely for store brands because volume planning uses multiple lines.
What are the most common bottlenecks for Delsym (dextromethorphan ER) supply?
Featured-snippet answer: The bottlenecks are usually upstream and format-specific: polymeric ER intermediate availability, viscosity and stability constraints for oral liquids, and packaging component lead times.
Specific risk points
- Polymer-salt intermediate procurement: timing and spec qualification can drive production holds.
- Oral liquid microbiological controls: preservative strategy and water activity drive batch acceptance.
- Container-closure system availability: child-resistant caps and bottle supply are recurring constraints during market spikes.
Where does Delsym fit in the Orange Book ecosystem for exclusivity?
Featured-snippet answer: Delsym is a small-molecule OTC cough suppressant; the Orange Book mapping is usually less actionable for “supplier” identification than for prescription branded drugs because OTC products typically do not use the same Orange Book patent listing model.
What matters for supplier decisions
For OTC dextromethorphan liquids, supplier risk is more often managed through:
- monograph compliance and formulation equivalence,
- current good manufacturing practice (cGMP) documentation,
- QMS qualification of the supplier’s manufacturing and testing.
How does Delsym compare to generic extended-release dextromethorphan liquids on supply?
Featured-snippet answer: Generics compete on access to the same API class, but “who can reliably supply” depends on whether a manufacturer can consistently hit ER suspension performance and fill-finish specs.
Why supply reliability can diverge
- Some manufacturers have strong ER liquid line experience and qualify polymeric carrier handling faster.
- Others rely on different particle prep routes that can fail performance specs at scale.
What packaging and logistics suppliers affect Delsym availability?
Featured-snippet answer: Packaging suppliers most often include the bottle, cap, and carton/label ecosystem, while logistics suppliers cover warehouse staging and retail distribution.
Operational interfaces that create delays
- cap blister and tamper mechanism lead times
- label printing and serialization windows
- distribution slotting for seasonal peaks
Key Takeaways
- Delsym is a dextromethorphan-based extended-release oral liquid; supplier identification is a multi-layer problem spanning API/ER intermediate, finished-dose manufacturing, and packaging/fill-finish.
- “Delsym supplier” typically changes with NDC/strength/pack configuration because production is often outsourced and site rotation is common.
- The most common supply bottlenecks for ER dextromethorphan liquids sit in polymeric ER intermediate availability, oral-liquid stability and microbiology controls, and container-closure component lead times.
- For actionable supplier mapping, the most reliable inputs are the label’s “manufactured for/ by” entity and NDC-linked manufacturing details, then cross-walk to ingredient and excipient qualification records.
FAQs
- Who is the labeler/distributor for Delsym in the US?
- Which ingredient form does Delsym typically use for extended release: dextromethorphan polistirex or dextromethorphan HBr?
- Can generic extended-release dextromethorphan syrups use different suppliers and still meet performance specs?
- What parts of the Delsym packaging system are most likely to cause supply disruptions during peak cold-and-flu seasons?
- How do manufacturers qualify polymeric extended-release intermediates for dextromethorphan ER liquids?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-06-09)
